Patient Perspective: Patients With EGFR+ NSCLC May Still Opt for Quality Over Quantity After FLAURA2
In light of recent data from the study of osimertinib with or without chemotherapy, patient advocate Ivy Elkins said the results may sway some to add chemo to their first-line treatment plan. However, for others, the impact on quality of life will not be worth it. Read more
When novel agents demonstrate high rates of durable treatment response but comparative outcome data with standard treatments are lacking, it is important to have methods to translate those treatments to different settings. Read more
During the 2023 World Conference on Lung Cancer, Dr. Stephen Chun said long-term data show intensity-modulated radiation therapy offers an overall survival benefit and reduced toxicity compared to 3D conformal radiation therapy. Read more
LungCAN Co-Chair Dusty Donaldson says training program helped just two advocates reach more than 630 million people in 32 states and five countries. Read more
Dr. Jennifer King brings expertise in molecular targets for cancer therapeutics as well as executive-level experience implementing strategic initiatives to the scientific affairs team. Read more
Dr. Jeffrey A. Bogart says that despite evidence that twice-daily radiotherapy has positive impacts on survival, the treatment has not been routinely adopted. However, considerable uncertainty remains regarding the optimal dose of once-daily radiotherapy. Read more
Dr. Jens Vogel-Claussen says the PLCOm2012 model, which includes family history and other factors, detected 97% of lung cancer cases compared to a 77% detection rate with NELSON criteria. Read more
A multivariate analysis presented by Dr. Andrea Wolf during the World Conference on Lung Cancer shows IASLC models performed well compared to other models. However, there is room for improvement, she said. Read more
Keynote addresses from renowned investigators Dr. Drew Pardoll and Prof. Laurence Zitvogel will bookend the conference. Learn more in a Q&A with the meeting chairs. Read more
October saw two approvals from the US FDA as well as caution from the agency’s Oncologic Drug Advisory Committee regarding the interpretation of CodeBreak 200 data; Takeda announces withdrawal of mobocertinib. Read more